This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carel, J.-C. Articles by Chaussain, J.-L. Search for Related Content PubMed PubMed Citation Articles by Carel, J.-C. Articles by Chaussain, J.-L.

Near Normalization of Final Height with Adapted Doses of Growth Hormone in Turner’s Syndrome

Department of Pediatric Endocrinology and INSERM U-342 (J.-C.C., L.M., C.G., J.-L.C.), Hôpital Saint Vincent de Paul, Paris; and Laboratoire Sanofi-Winthrop (C.G., J.-P.D.), Paris, France

Address all correspondence and requests for reprints to: Dr. Jean-Claude Carel, INSERM U-342, Hôpital Saint Vincent de Paul, 82 avenue Denfert Rochereau, 75014 Paris, France. E-mail: carel{at}cochin.inserm.fr

An adapted GH dose regimen was evaluated in 14 untreated patients with Turner’s syndrome. The initial GH dose (0.7 U/kg·BW) was increased by 0.7 U/kg·BW, up to a maximum of 2.1 U/kg·BW, when growth velocity (GV) declined to less than 200% of the pretreatment level. These patients were compared to a group of 17 patients with similar initial characteristics, who received a fixed dose of 0.9 U/kg·BW GH. Tolerance to both GH regimens was excellent. The adapted GH doses only partially prevented the waning effect observed with conventional doses of GH, and the initial goal of doubling GV was only achieved in 42% of the 112 patient-semesters. Doubling the GH dose from 0.7 to 1.4 U/kg·BW increased the GV by 1.6 ± 1.8 cm/yr (P < 0.006); increasing the GH dose from 1.4 to 2.1 U/kg·BW increased GV by 0.8 ± 1.3 cm/yr (P = NS). The overall height gain during the 4-yr trial was 25.6 ± 3.9 cm in the adapted dose group and 21.8 ± 3.9 cm in the conventional group (P < 0.02). Final height (FH) results were obtained in 12 of 14 patients in the adapted dose group and all 17 patients in the conventional group and compared to the predicted FH using Lyon’s method. The estimated height benefit was 10.6 ± 3.8 cm in the adapted dose group compared to 5.2 ± 3.7 cm in the conventional group (P < 0.01). Eighty-three percent of the patients in the adapted dose group had an FH superior or equal to -2 SD score for the general population compared to 29% in the conventional group. In conclusion, a marked increment in the GH dose in girls with Turner’s syndrome associated with a relatively late age at introduction of estrogen therapy brought 83% of the patients into the lower range of the normal height distribution of the general population.

This article has been cited by other articles:

				M. L. Davenport, B. J. Crowe, S. H. Travers, K. Rubin, J. L. Ross, P. Y. Fechner, D. F. Gunther, C. Liu, M. E. Geffner, K. Thrailkill, et al. Growth Hormone Treatment of Early Growth Failure in Toddlers with Turner Syndrome: A Randomized, Controlled, Multicenter Trial J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3406 - 3416. [Abstract] [Full Text] [PDF]

				W. F. Blum, B. J. Crowe, C. A. Quigley, H. Jung, D. Cao, J. L. Ross, L. Braun, G. Rappold, and for the SHOX Study Group Growth Hormone Is Effective in Treatment of Short Stature Associated with Short Stature Homeobox-Containing Gene Deficiency: Two-Year Results of a Randomized, Controlled, Multicenter Trial J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 219 - 228. [Abstract] [Full Text] [PDF]

				M D C Donaldson, E J Gault, K W Tan, and D B Dunger Optimising management in Turner syndrome: from infancy to adult transfer Arch. Dis. Child., June 1, 2006; 91(6): 513 - 520. [Abstract] [Full Text] [PDF]

				L. Soriano-Guillen, J. Coste, E. Ecosse, J. Leger, M. Tauber, S. Cabrol, M. Nicolino, R. Brauner, the StaTur Study Group, J.-L. Chaussain, et al. Adult Height and Pubertal Growth in Turner Syndrome after Treatment with Recombinant Growth Hormone J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5197 - 5204. [Abstract] [Full Text] [PDF]

				J.-C. Carel, E. Ecosse, I. Bastie-Sigeac, S. Cabrol, M. Tauber, J. Leger, M. Nicolino, R. Brauner, J.-L. Chaussain, and J. Coste Quality of Life Determinants in Young Women with Turner's Syndrome after Growth Hormone Treatment: Results of the StaTur Population-Based Cohort Study J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 1992 - 1997. [Abstract] [Full Text] [PDF]

				G. Massa, C. Heinrichs, S. Verlinde, M. Thomas, J. P. Bourguignon, M. Craen, I. Francois, M. Du Caju, M. Maes, and J. De Schepper Late or Delayed Induced or Spontaneous Puberty in Girls with Turner Syndrome Treated with Growth Hormone Does Not Affect Final Height J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4168 - 4174. [Abstract] [Full Text] [PDF]

				Y. K. van Pareren, S. M. P. F. de Muinck Keizer-Schrama, T. Stijnen, T. C. J. Sas, M. Jansen, B. J. Otten, J. J. G. Hoorweg-Nijman, T. Vulsma, W. H. Stokvis-Brantsma, C. W. Rouwe, et al. Final Height in Girls with Turner Syndrome after Long-Term Growth Hormone Treatment in Three Dosages and Low Dose Estrogens J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1119 - 1125. [Abstract] [Full Text] [PDF]

				Y. K. van Pareren, S. M. P. F. de Muinck Keizer-Schrama, T. Stijnen, T. C. J. Sas, and S. L. S. Drop Effect of Discontinuation of Long-Term Growth Hormone Treatment on Carbohydrate Metabolism and Risk Factors for Cardiovascular Disease in Girls with Turner Syndrome J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5442 - 5448. [Abstract] [Full Text] [PDF]

				G. A. Rappold, M. Fukami, B. Niesler, S. Schiller, W. Zumkeller, M. Bettendorf, U. Heinrich, E. Vlachopapadoupoulou, T. Reinehr, K. Onigata, et al. Deletions of the Homeobox Gene SHOX (Short Stature Homeobox) Are an Important Cause of Growth Failure in Children with Short Stature J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1402 - 1406. [Abstract] [Full Text] [PDF]

				M. Elsheikh, D. B. Dunger, G. S. Conway, and J. A. H. Wass Turner's Syndrome in Adulthood Endocr. Rev., February 1, 2002; 23(1): 120 - 140. [Abstract] [Full Text] [PDF]

				P. Saenger, K. A. Wikland, G. S. Conway, M. Davenport, C. H. Gravholt, R. Hintz, O. Hovatta, M. Hultcrantz, K. Landin-Wilhelmsen, A. Lin, et al. Recommendations for the Diagnosis and Management of Turner Syndrome J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3061 - 3069. [Abstract] [Full Text] [PDF]

				E. O. Reiter, S. L. Blethen, J. Baptista, and L. Price Early Initiation of Growth Hormone Treatment Allows Age-Appropriate Estrogen Use in Turner's Syndrome J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1936 - 1941. [Abstract] [Full Text]

				M. B. Ranke, A. Lindberg, P. Chatelain, P. Wilton, W. Cutfield, K. Albertsson-Wikland, and D. A. Price Prediction of Long-Term Response to Recombinant Human Growth Hormone in Turner Syndrome: Development and Validation of Mathematical Models J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4212 - 4218. [Abstract] [Full Text]

				C G D BROOK;, C. J H KELNAR;, and P. BETTS Controversy: Which children should receive growth hormone treatment Arch. Dis. Child., August 1, 2000; 83(2): 176 - 178. [Full Text] [PDF]

				T. C. J. Sas, S. M. P. F. de Muinck Keizer-Schrama, T. Stijnen, H. J. Aanstoot, and S. L. S. Drop Carbohydrate Metabolism during Long-Term Growth Hormone (GH) Treatment and after Discontinuation of GH Treatment in Girls with Turner Syndrome Participating in a Randomized Dose-Response Study J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 769 - 775. [Abstract] [Full Text]

				H. Guyda Four Decades of Growth Hormone Therapy for Short Children: What Have We Achieved? J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4307 - 4316. [Full Text]

				T. Sas Normalization of Height in Girls with Turner Syndrome after Long-Term Growth Hormone Treatment: Results of a Randomized Dose-Response Trial J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4607 - 4612. [Abstract] [Full Text]

				Body Proportions during Long-Term Growth Hormone Treatment in Girls with Turner Syndrome Participating in a Randomized Dose-Response Trial J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4622 - 4628. [Abstract] [Full Text]